Eric Lefkofsky: How He Led Tempus to Offer More Than Medicines
Under the leadership of Eric Lefkofsky, Tempus is applying machine learning to clinical and molecular data and patient assessments to discover personalized treatments for cancer. The firm’s algorithms are helping to improve the development and delivery of precision medicines and identify new ways to prevent cancer recurrence. Eric Lefkofsky explains that its innovations in computing power and artificial intelligence for medicine enable clinical staff to improve the care of patients through improved detection and treatment of cancer.
The company’s healthcare solutions enable physicians to find and treat diseases better and more effectively. Under the leadership of Eric Lefkofsky, Tempus’ cloud-based architecture collects and harmonizes patient data from multiple sources. These sources include electronic health records (EHRs), lab tests, tissue biopsies, genomic sequencing, and much more. Tempus’ precision medicine technology platform combines that data into a single integrated view, allowing doctors to deliver the best patient outcomes.
Eric Lefkofsky points out that while cancer research is well underway with novel therapies in early clinical trials or under review, personalized medicines for each patient are sorely lacking. The task of learning how cancer evolves, matures, and responds to treatment is still primarily the domain of well-resourced scientific labs with access to huge amounts of data. For Eric Lefkofsky, other innovative approaches that help target treatment, like vaccine vaccines and checkpoint inhibitors, focus on other organs in the body.
When taken in isolation, these approaches could work very well, but when used in combination, achieving the best outcome remains elusive. Eric Lefkofsky finally adds that, since its inception, Tempus has focused on the application of artificial intelligence to in silico data. These artificial intelligence techniques are being developed to provide clinicians with personalized medicine that improves outcomes and lowers costs and also enables researchers and developers to accelerate the development of new drugs and therapies.